PURPOSE: The Ocular Hypertension Treatment Study (OHTS) seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss and/or optic nerve damage in ocular hypertensive subjects at risk for developing primary open-angle glaucoma. This study evaluates the baseline visual field test characteristics (visual field status, reliability properties, etc.) of patients who underwent eligibility visual field testing for entry to the OHTS. DESIGN: Cross-sectional study of baseline data as part of a longitudinal randomized clinical trial. PARTICIPANTS: Two thousand eight hundred nineteen ocular hypertensive individuals, aged 40 to 80 (mean age, 55). METHODS: Subjects underwent at least two Humphrey Field Analyzer Program 30-2 Full Threshold visual field examinations in both eyes for study eligibility. A third examination was performed if a prior test was abnormal, questionable, or unreliable. For final eligibility, two sets of visual field examinations had to meet OHTS criteria for reliability and had to be classified as "normal." All OHTS visual field tests of potential subjects were submitted for eligibility assessment to the OHTS Visual Field Reading Center. MAIN OUTCOME MEASURES: The percentage of visual fields that were normal and reliable according to OHTS criteria. RESULTS: Of the subset of 2304 subjects who completed the eligibility assessments, 1828 (79%) were OHTS-eligible based on visual field test requirements. A third eligibility test was required for 11% of all eyes because of unreliable, questionable, or abnormal test results. With the 33% fixation loss cutoff in the OHTS, 97% of all eligibility visual field examinations were reliable and 3% were unreliable. The most frequent cause (69.5%) of unreliability was excessive fixation losses. CONCLUSIONS: Permitting one repeat test after an abnormal or unreliable test allowed an extra 560 patients to be "eligible" for the study based on visual field tests. A clinical screening review of otherwise normal and reliable tests was not restrictive. The adoption of a 33% fixation loss cutoff significantly reduced the number of required retests and prevented study rejection of 89 patients.
RCT Entities:
PURPOSE: The Ocular Hypertension Treatment Study (OHTS) seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss and/or optic nerve damage in ocular hypertensive subjects at risk for developing primary open-angle glaucoma. This study evaluates the baseline visual field test characteristics (visual field status, reliability properties, etc.) of patients who underwent eligibility visual field testing for entry to the OHTS. DESIGN: Cross-sectional study of baseline data as part of a longitudinal randomized clinical trial. PARTICIPANTS: Two thousand eight hundred nineteen ocular hypertensive individuals, aged 40 to 80 (mean age, 55). METHODS: Subjects underwent at least two Humphrey Field Analyzer Program 30-2 Full Threshold visual field examinations in both eyes for study eligibility. A third examination was performed if a prior test was abnormal, questionable, or unreliable. For final eligibility, two sets of visual field examinations had to meet OHTS criteria for reliability and had to be classified as "normal." All OHTS visual field tests of potential subjects were submitted for eligibility assessment to the OHTS Visual Field Reading Center. MAIN OUTCOME MEASURES: The percentage of visual fields that were normal and reliable according to OHTS criteria. RESULTS: Of the subset of 2304 subjects who completed the eligibility assessments, 1828 (79%) were OHTS-eligible based on visual field test requirements. A third eligibility test was required for 11% of all eyes because of unreliable, questionable, or abnormal test results. With the 33% fixation loss cutoff in the OHTS, 97% of all eligibility visual field examinations were reliable and 3% were unreliable. The most frequent cause (69.5%) of unreliability was excessive fixation losses. CONCLUSIONS: Permitting one repeat test after an abnormal or unreliable test allowed an extra 560 patients to be "eligible" for the study based on visual field tests. A clinical screening review of otherwise normal and reliable tests was not restrictive. The adoption of a 33% fixation loss cutoff significantly reduced the number of required retests and prevented study rejection of 89 patients.
Authors: Karun S Arora; Michael V Boland; David S Friedman; Joan L Jefferys; Sheila K West; Pradeep Y Ramulu Journal: Ophthalmology Date: 2013-08-30 Impact factor: 12.079
Authors: Richard A Levine; Shaban Demirel; Juanjuan Fan; John L Keltner; Chris A Johnson; Michael A Kass Journal: Invest Ophthalmol Vis Sci Date: 2006-09 Impact factor: 4.799
Authors: Cynthia Owsley; Gerald McGwin; Beth T Stalvey; June Weston; Karen Searcey; Christopher A Girkin Journal: J Natl Med Assoc Date: 2008-09 Impact factor: 1.798
Authors: Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson Journal: Arch Ophthalmol Date: 2010-03
Authors: James D Brandt; Mae O Gordon; Feng Gao; Julia A Beiser; J Phillip Miller; Michael A Kass Journal: Ophthalmology Date: 2011-06-25 Impact factor: 12.079
Authors: Bharathi Govindarajan; Anna Junk; Mabel Algeciras; Robert G Salomon; Sanjoy K Bhattacharya Journal: Mol Vis Date: 2009-06-01 Impact factor: 2.367